# EASD 2026 study: E1, congress penetration and latency

**Generated by** `scripts/easd-2026-study/e1.ts` from a read-only pull (2026-08-22 → 2026-10-11, pulled 2026-10-11T16:56:27.066Z) and the hand ledger `docs/evidence/easd-2026-e1-ledger.json`. Rule: prereg §4 E1. The Saudi rows are the post-registration arm (D10).

**Detection limit.** New URLs only: a page cited before the congress and later updated with congress content is not re-read; the text route still detects an answer reporting a readout result.

**Screen.** New (series, URL) pairs in the congress and after windows: 5268 (5266 unique URLs). Fetched and read by script for congress or readout terms; 114 candidates read by hand; 5154 carried no such term; 947 could not be read (fetch failure or HTTP ≥ 400).

**Hand ledger.** Qualifying sources 10; candidates excluded on reading 112. Answers whose text reports a readout result: 0; text candidates excluded on reading 30.

## uae-glp1: answers citing a congress-derived source or reporting a readout result

| Cycle | Date | Window | Perplexity | Gemini | ChatGPT | Claude |
|---|---|---|---|---|---|---|
| `UAE-C01` | 2026-08-22 | before-v4 | 0/54 | 0/60 | 0/60 | 0/60 |
| `UAE-C02` | 2026-08-24 | before-v4 | 0/60 | 0/60 | 0/60 | 0/60 |
| `UAE-C03` | 2026-08-26 | before-v4 | 0/60 | 0/60 | 0/60 | 0/60 |
| `UAE-C04` | 2026-08-28 | before-v4 | 0/60 | 0/60 | 0/60 | 0/60 |
| `UAE-C05` | 2026-08-30 | before-v4 | 0/59 | 0/60 | 0/60 | 0/60 |
| `UAE-C06` | 2026-09-04 | before-v4 | 0/60 | 0/60 | 0/60 | 0/60 |
| `UAE-C07` | 2026-09-09 | before-v4 | 0/60 | 0/60 | 0/60 | 0/60 |
| `UAE-C08` | 2026-09-11 | before-v4 | 0/60 | 0/60 | 0/60 | 0/60 |
| `UAE-C09` | 2026-09-14 | before-v4 | 0/57 | 0/59 | 0/60 | 0/60 |
| `UAE-C10` | 2026-09-16 | before-v4 | 0/56 | 0/60 | 0/60 | 0/60 |
| `UAE-C11` | 2026-09-21 | before-v4 | 0/59 | 0/60 | 0/60 | 0/60 |
| `UAE-C12` | 2026-09-23 | before-v4 | 0/60 | 0/60 | 0/60 | 0/60 |
| `UAE-C13` | 2026-09-25 | before-v4 | 0/60 | 0/60 | 0/60 | 0/60 |
| `UAE-C14` | 2026-09-27 | before-v5 | 0/58 | 0/60 | 0/60 | 0/60 |
| `UAE-C15` | 2026-09-29 | during | 0/60 (+8 unverified) | 0/60 (+44 unverified) | 0/60 (+5 unverified) | 0/60 (+6 unverified) |
| `UAE-C16` | 2026-10-04 | after | 3/60 (+8 unverified) | 0/60 (+44 unverified) | 0/60 (+4 unverified) | 0/60 (+14 unverified) |
| `UAE-C18` | 2026-10-06 | after | 2/60 (+9 unverified) | 1/60 (+45 unverified) | 0/60 (+7 unverified) | 0/60 (+9 unverified) |
| `UAE-C19` | 2026-10-07 | after | 0/60 (+7 unverified) | 0/60 (+45 unverified) | 0/60 (+4 unverified) | 0/60 (+10 unverified) |
| `UAE-C20` | 2026-10-08 | after | 0/60 (+5 unverified) | 0/60 (+43 unverified) | 0/60 (+8 unverified) | 0/60 (+11 unverified) |
| `UAE-C21` | 2026-10-09 | after | 0/60 (+7 unverified) | 0/60 (+46 unverified) | 0/60 (+6 unverified) | 0/60 (+10 unverified) |
| `UAE-C22` | 2026-10-10 | after | 0/60 (+29 unverified) | 0/60 (+45 unverified) | 0/60 (+9 unverified) | 0/60 (+9 unverified) |
| `UAE-C23` | 2026-10-11 | after | 0/60 (+27 unverified) | 0/60 (+51 unverified) | 0/60 (+16 unverified) | 0/60 (+13 unverified) |

## singapore-sglt2: answers citing a congress-derived source or reporting a readout result

| Cycle | Date | Window | Perplexity | Gemini | ChatGPT | Claude |
|---|---|---|---|---|---|---|
| `SG-C01` | 2026-08-22 | before-v4 | 0/22 | 0/26 | 0/26 | 0/26 |
| `SG-C02` | 2026-08-24 | before-v4 | 0/26 | 0/26 | 0/26 | 0/26 |
| `SG-C03` | 2026-08-26 | before-v4 | 0/26 | 0/26 | 0/26 | 0/26 |
| `SG-C04` | 2026-08-28 | before-v4 | 0/26 | 0/26 | 0/26 | 0/26 |
| `SG-C05` | 2026-08-30 | before-v4 | 0/26 | 0/26 | 0/26 | 0/26 |
| `SG-C06` | 2026-09-04 | before-v4 | 0/26 | 0/26 | 0/26 | 0/26 |
| `SG-C07` | 2026-09-06 | before-v4 | 0/26 | 0/26 | 0/26 | 0/26 |
| `SG-C08` | 2026-09-08 | before-v4 | 0/26 | 0/26 | 0/26 | 0/26 |
| `SG-C09` | 2026-09-10 | before-v4 | 0/26 | 0/26 | 0/26 | 0/26 |
| `SG-C10` | 2026-09-13 | before-v4 | 0/26 | 0/26 | 0/26 | 0/26 |
| `SG-C11` | 2026-09-15 | before-v4 | 0/26 | 0/26 | 0/26 | 0/26 |
| `SG-C12` | 2026-09-17 | before-v4 | 0/26 | 0/26 | 0/26 | 0/26 |
| `SG-C13` | 2026-09-19 | before-v4 | 0/26 | 0/25 | 0/26 | 0/26 |
| `SG-C14` | 2026-09-21 | before-v4 | 0/25 | 0/26 | 0/26 | 0/26 |
| `SG-C15` | 2026-09-26 | before-v4 | 0/26 | 0/26 | 0/26 | 0/26 |
| `SG-C17` | 2026-10-02 | during | 0/26 (+7 unverified) | 0/26 (+15 unverified) | 0/26 (+1 unverified) | 0/26 |
| `SG-C18` | 2026-10-05 | after | 0/26 (+6 unverified) | 0/26 (+18 unverified) | 0/26 (+1 unverified) | 0/26 |
| `SG-C19` | 2026-10-06 | after | 0/26 (+6 unverified) | 0/26 (+10 unverified) | 0/26 (+4 unverified) | 0/26 (+1 unverified) |
| `SG-C20` | 2026-10-07 | after | 0/26 (+3 unverified) | 0/26 (+17 unverified) | 0/26 (+3 unverified) | 0/26 (+1 unverified) |
| `SG-C21` | 2026-10-08 | after | 0/26 (+3 unverified) | 0/26 (+14 unverified) | 0/26 (+4 unverified) | 0/26 |
| `SG-C22` | 2026-10-09 | after | 0/26 (+2 unverified) | 0/26 (+13 unverified) | 0/26 (+1 unverified) | 0/26 (+1 unverified) |
| `SG-C23` | 2026-10-10 | after | 0/26 (+3 unverified) | 0/26 (+16 unverified) | 0/26 (+4 unverified) | 0/26 (+2 unverified) |
| `SG-C24` | 2026-10-11 | after | 0/26 (+4 unverified) | 0/26 (+19 unverified) | 0/26 (+4 unverified) | 0/26 (+2 unverified) |

## saudi-t1d (POST-REGISTRATION): answers citing a congress-derived source or reporting a readout result

| Cycle | Date | Window | Perplexity | Gemini | ChatGPT | Claude |
|---|---|---|---|---|---|---|
| `SA-C01` | 2026-08-24 | before-v4 | 0/56 | 0/56 | 0/56 | 0/56 |
| `SA-C02` | 2026-08-27 | before-v4 | 0/56 | 0/56 | 0/56 | 0/56 |
| `SA-C03` | 2026-08-30 | before-v4 | 0/54 | 0/55 | 0/56 | 0/56 |
| `SA-C04` | 2026-09-01 | before-v4 | 0/56 | 0/56 | 0/56 | 0/56 |
| `SA-C05` | 2026-09-03 | before-v4 | 0/56 | 0/56 | 0/56 | 0/56 |
| `SA-C06` | 2026-09-08 | before-v4 | 0/55 | 0/56 | 0/56 | 0/56 |
| `SA-C07` | 2026-09-10 | before-v4 | 0/56 | 0/56 | 0/56 | 0/56 |
| `SA-C08` | 2026-09-14 | before-v4 | 0/55 | 0/56 | 0/56 | 0/56 |
| `SA-C09` | 2026-09-16 | before-v4 | 0/53 | 0/55 | 0/56 | 0/56 |
| `SA-C10` | 2026-09-21 | before-v4 | 0/51 | 0/56 | 0/56 | 0/56 |
| `SA-C11` | 2026-09-26 | before-v4 | 0/52 | 0/56 | 0/56 | 0/56 |
| `SA-C13` | 2026-10-04 | after | 0/56 (+10 unverified) | 0/56 (+52 unverified) | 0/56 (+3 unverified) | 0/56 (+10 unverified) |
| `SA-C14` | 2026-10-05 | after | 2/56 (+12 unverified) | 0/56 (+50 unverified) | 0/56 (+5 unverified) | 0/53 (+7 unverified) |
| `SA-C15` | 2026-10-06 | after | 1/56 (+16 unverified) | 0/56 (+52 unverified) | 0/56 (+3 unverified) | 0/56 (+6 unverified) |
| `SA-C16` | 2026-10-07 | after | 0/56 (+12 unverified) | 1/56 (+53 unverified) | 0/56 (+2 unverified) | 0/56 (+8 unverified) |
| `SA-C17` | 2026-10-08 | after | 0/56 (+5 unverified) | 0/56 (+50 unverified) | 0/56 (+3 unverified) | 1/56 (+7 unverified) |
| `SA-C18` | 2026-10-09 | after | 0/56 (+3 unverified) | 0/56 (+50 unverified) | 0/56 (+5 unverified) | 0/56 (+12 unverified) |
| `SA-C19` | 2026-10-10 | after | 0/56 (+3 unverified) | 0/56 (+54 unverified) | 0/56 (+5 unverified) | 0/56 (+11 unverified) |
| `SA-C20` | 2026-10-11 | after | 0/56 (+4 unverified) | 0/56 (+50 unverified) | 0/56 (+6 unverified) | 0/56 (+11 unverified) |

## Inspection coverage (congress and after windows)

The text route reads every answer, so it is complete. The source route depends on reading the cited pages: the table gives, per engine and window, the answers citing at least one new URL, those citing at least one page that could not be read (unverified, never counted as negative), and the share of new-URL citations that were read.

| Series | Engine | Window | Answers | Citing a new URL | Citing an unreadable page | New-URL citations read |
|---|---|---|---|---|---|---|
| saudi-t1d | Claude | after | 445 | 212 | 72 | 77.1% of 371 |
| saudi-t1d | Gemini | after | 448 | 435 | 412 | 68.5% of 5158 |
| saudi-t1d | ChatGPT | after | 448 | 119 | 32 | 83.2% of 226 |
| saudi-t1d | Perplexity | after | 448 | 340 | 66 | 90.1% of 778 |
| singapore-sglt2 | Claude | after | 182 | 31 | 7 | 82.6% of 46 |
| singapore-sglt2 | Claude | during | 26 | 5 | 0 | 100.0% of 5 |
| singapore-sglt2 | Gemini | after | 182 | 158 | 107 | 76.2% of 1267 |
| singapore-sglt2 | Gemini | during | 26 | 24 | 15 | 77.3% of 194 |
| singapore-sglt2 | ChatGPT | after | 182 | 59 | 21 | 74.2% of 89 |
| singapore-sglt2 | ChatGPT | during | 26 | 1 | 1 | 0.0% of 1 |
| singapore-sglt2 | Perplexity | after | 182 | 73 | 27 | 89.3% of 308 |
| singapore-sglt2 | Perplexity | during | 26 | 19 | 7 | 92.4% of 132 |
| uae-glp1 | Claude | after | 420 | 261 | 76 | 83.9% of 628 |
| uae-glp1 | Claude | during | 60 | 24 | 6 | 86.5% of 52 |
| uae-glp1 | Gemini | after | 420 | 418 | 320 | 87.2% of 6006 |
| uae-glp1 | Gemini | during | 60 | 60 | 44 | 89.2% of 807 |
| uae-glp1 | ChatGPT | after | 420 | 197 | 54 | 84.7% of 378 |
| uae-glp1 | ChatGPT | during | 60 | 16 | 5 | 81.5% of 27 |
| uae-glp1 | Perplexity | after | 420 | 372 | 97 | 87.6% of 1038 |
| uae-glp1 | Perplexity | during | 60 | 40 | 8 | 79.6% of 103 |

Most frequent unreadable domains, uae-glp1: [gemini-only host] (71), [gemini-only host] (50), [local-clinic-or-hospital-022] (48), marketresearch.com (44), qz.com (36), arabianbusiness.com (34), [commercial-or-unclassified-site-192] (31), goodrx.com (29), forbes.com (27), [gemini-only host] (26).

Most frequent unreadable domains, singapore-sglt2: mims.com (305), goodrx.com (18), [pharmacy-39] (13), dailypharm.com (11), journal-news.com (5), diatribe.org (5), nhathuocankhang.com (5), [clinic-or-hospital-055] (5), accessdata.fda.gov (4), [gemini-only host] (4).

Most frequent unreadable domains, saudi-t1d: [local-pharmacy-45] (412), [local-retailer-or-delivery-20] (298), [local-commercial-or-unclassified-site-120] (223), [local-pharmacy-33] (134), [local-retailer-or-delivery-05] (108), breakthrought1d.org.au (46), researchgate.net (44), diabetesjournals.org (43), [local-clinic-or-hospital-153] (31), indiamart.com (27).

## Latency (days from presentation to the first cycle with a qualifying answer)

| Series | Readout | Perplexity | Gemini | ChatGPT | Claude |
|---|---|---|---|---|---|
| uae-glp1 | REIMAGINE 1 (CagriSema), LBA 11/12 | not observed by day 12.1 | not observed by day 12.1 | not observed by day 12.1 | not observed by day 12.1 |
| uae-glp1 | TRIUMPH-2 (retatrutide) | not observed by day 11.3 | not observed by day 11.3 | not observed by day 11.3 | not observed by day 11.3 |
| uae-glp1 | CagriSema appetite, abstract 122 | not observed by day 11.1 | not observed by day 11.1 | not observed by day 11.1 | not observed by day 11.1 |
| uae-glp1 | ACHIEVE programme (orforglipron) | not observed by day 10.3 | not observed by day 10.3 | not observed by day 10.3 | not observed by day 10.3 |
| singapore-sglt2 | SMARTEST (SGLT2 vs metformin first line) | not observed by day 10.3 | not observed by day 10.3 | not observed by day 10.3 | not observed by day 10.3 |
| uae-glp1 | ACHIEVE-4 kidney outcomes, LBA 25 | not observed by day 10 | not observed by day 10 | not observed by day 10 | not observed by day 10 |
| uae-glp1 | Tirzepatide vs semaglutide proteomics, LBA 29 | not observed by day 10 | not observed by day 10 | not observed by day 10 | not observed by day 10 |
| uae-glp1 | OCTANE (switch to oral semaglutide, real-world), LBA 59 (post-registration, D3) | 4.2 (`UAE-C16`) | 6.2 (`UAE-C18`) | not observed by day 11.2 | not observed by day 11.2 |
| saudi-t1d | EASD 2026 type 1 diabetes programme (agent set + teplizumab abstracts) (post-registration, D10) | not observed by day 12.4 | not observed by day 12.4 | not observed by day 12.4 | 9.4 (`SA-C17`) |
| uae-glp1 | Other EASD 2026 data (not in the readout set) (post-registration, E1 classes (c)/(d)) | 6.3 (`UAE-C16`) | 8.3 (`UAE-C18`) | not observed by day 13.3 | not observed by day 13.3 |
| singapore-sglt2 | Other EASD 2026 data (not in the readout set) (post-registration, E1 classes (c)/(d)) | not observed by day 13.3 | not observed by day 13.3 | not observed by day 13.3 | not observed by day 13.3 |
| saudi-t1d | Other EASD 2026 data (not in the readout set) (post-registration, E1 classes (c)/(d)) | 7.4 (`SA-C14`) | 9.4 (`SA-C16`) | not observed by day 13.4 | 10.4 (`SA-C17`) |

### Readout data reaching another arm

A source carrying a readout registered for one series was cited in an answer of another series. The latency table above counts a readout only in its registered series, so these are reported here and never enter it.

| Readout | Registered series | Answer series | Engine | First cycle | Days from presentation | Content at citation |
|---|---|---|---|---|---|---|
| TRIUMPH-2 (retatrutide) | uae-glp1 | saudi-t1d | Claude | `SA-C17` | 8.4 | **unverified** (page carries it today; not shown to have carried it when cited) |

### Corrected classifications

Each correction keeps the earlier classification. The current classification is the one the tables use.

- saudi-t1d · https://diatribe.org/diabetes-research/top-diabetes-news-easd-2026 — revised 2026-10-11: was d-media (Other EASD 2026 data (not in the readout set)), now d-media (EASD 2026 type 1 diabetes programme (agent set + teplizumab abstracts); TRIUMPH-2 (retatrutide); Other EASD 2026 data (not in the readout set)). Full re-read of the article. Two of its items carry readouts without naming the trial, which the term screen cannot see. (1) "Retatrutide Promotes Weight Loss in People With Type 2 Diabetes": a late-stage trial of 1,152 people with type 2 diabetes and overweight or obesity over 80 weeks, nearly 19% weight loss at the highest dose and A1C -1.45%. These match the TRIUMPH-2 presentation of 30 Sep (1,152 adults, 80 weeks, 18.8% at 12 mg on the treatment-regimen estimand; Lilly's release gives 20.8% on the efficacy estimand). Class (d) turns on the article date (5 Oct) and its reporting congress data; a topline release before the congress does not change it. (2) "Tzield Therapy Begins in European Countries": first real-world teplizumab courses in stage 2 type 1 diabetes in the UK (10 people) and Italy (18 children), reported in the EASD 2026 round-up; teplizumab abstracts are in the Saudi programme readout (D10). The abstract number (373, 376 or 745) was not matched. The earlier entry recorded TRIUMPH-2 in its note but not in its readouts.
  Content at citation: Cited by Claude, exact URL (not a redirect), in Saudi answer 87f5a541a5 of cycle SA-C17, captured 2026-10-08T16:31Z, three days after the article date (5 Oct). No archived copy exists (Wayback Machine: no snapshot, checked 11 Oct). The Tzield item is corroborated: the answer repeats it ("Real-world studies continue to provide evidence of its safety and efficacy as a therapy for slowing the progression of type 1 diabetes"; "temporary drops in white blood cell counts, rashes, and gastrointestinal issues"). The retatrutide item is not corroborated: the answer does not use it, and today's page cannot show it was there on 8 Oct.
  Unverified at citation (reported, never counted): TRIUMPH-2 (retatrutide).
  **Adjudication:** URL: https://diatribe.org/diabetes-research/top-diabetes-news-easd-2026, cited verbatim by Claude in one admitted Saudi answer (87f5a541a5, cycle SA-C17, 2026-10-08T16:31Z, a question asking for an evaluation of Tzield; question text withheld under protocol §10); cited in no UAE or Singapore answer. Registered eligibility: class (d), media dated 5 Oct (on or after 28 Sep) reporting congress data, so the answer counts as citing a congress-derived source. TRIUMPH-2: the article's retatrutide item satisfies the TRIUMPH-2 classification without naming the trial (same population, size, duration and effect as the 30 Sep presentation). Historical content: no archived copy; the article date precedes the answer by three days; the Tzield item is shown to have been present (the answer repeats it), the retatrutide item is not. Verdict: QUALIFYING SOURCE (class d) for the Saudi arm, labelled with the Saudi programme readout (teplizumab real-world item, verified at citation) and other EASD 2026 data. TRIUMPH-2 is UNVERIFIED AT CITATION: reported as unverified, not counted, and not treated as negative. It could never enter the registered TRIUMPH-2 cell, which belongs to the UAE series, where no answer cited this page: the registered UAE result stays "not observed by day 11.3".

## Ledger: qualifying sources

**Evidence note.** A source is classified from the page as fetched on the date shown. The fetch date is not the date the engine cited it, and a later fetch does not establish what the page said when cited. An unreadable new URL is unverified, never 'no congress content'.

| Series | URL (resolved) | As cited | Engines | First observed in an answer | Class | Readouts | Page date | Fetched | Qualifying sentence |
|---|---|---|---|---|---|---|---|---|---|
| saudi-t1d | https://diatribe.org/diabetes-research/top-diabetes-news-easd-2026 | direct | anthropic | 2026-10-08T16:31 | d-media | EASD 2026 type 1 diabetes programme (agent set + teplizumab abstracts); TRIUMPH-2 (retatrutide); Other EASD 2026 data (not in the readout set) | 2026-10-05 | 2026-10-11 | New insights on diabetes treatment, management, and technology emerged from the European Association for the Study of Diabetes (EASD) 2026 conference in Milan, Italy. |
| saudi-t1d | [gemini-only]/p1098 | Gemini redirect | google | 2026-10-07T16:32 | c-sponsor | Other EASD 2026 data (not in the readout set) | 2026-10-05 | 2026-10-10 | [quotation withheld: page cited only by Gemini] |
| saudi-t1d | https://sadanews.ps/en/news/339566.html | direct | perplexity | 2026-10-05T16:32 | d-media | Other EASD 2026 data (not in the readout set) | not printed | 2026-10-10 | The study's results, led by the University Medical Center in the German city of Ulm in collaboration with Boston Children's Hospital and Harvard Medical School in the United States, were presented on Friday at the annual meeting of the European Association for the Study of Diabetes, currently taking place in Milan, Italy. |
| uae-glp1 | https://biopharmadive.com/news/3-takeaways-from-european-obesity-scientific-meeting/831870 | direct | perplexity | 2026-10-04T14:02 | d-media | OCTANE (switch to oral semaglutide, real-world), LBA 59; Other EASD 2026 data (not in the readout set) | 2026-10-01 | 2026-10-10 | At EASD, it presented data from a “real world” study of de-identified patient data it did in conjunction with direct-to-consumer partner Ro. |
| uae-glp1 | https://biospace.com/press-releases/lillys-zepbound-tirzepatide-10-mg-and-15-mg-was-associated-with-more-weight-loss-than-wegovy-hd-semaglutide-injection-7-2-mg-in-a-new-indirect-treatment-comparison | direct | perplexity | 2026-10-04T14:02 | c-sponsor | Other EASD 2026 data (not in the readout set) | 2026-09-29 | 2026-10-10 | 1,2,3 These results, presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, add to the growing body of evidence comparing Zepbound and Wegovy, including SURMOUNT-5, a randomized controlled Phase 3b trial in which Zepbound 10 mg and 15 mg demonstrated superior weight loss compared with Wegovy 1.7 mg and 2.4 mg. |
| uae-glp1 | https://biospace.com/press-releases/people-switching-from-weight-loss-injections-to-novos-wegovy-pill-lost-4-1-body-weight-on-average-after-three-months-according-to-real-world-data-presented-at-easd2026 | direct | perplexity | 2026-10-04T14:02 | c-sponsor | OCTANE (switch to oral semaglutide, real-world), LBA 59 | 2026-09-30 | 2026-10-10 | 1 OCTANE was presented during a short oral session at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, on September 30, 2026. |
| uae-glp1 | https://cnbc.com/2026/09/30/eli-lilly-obesity-drug-amylin-tirzepatide-weight-loss-trial.html | direct | perplexity | 2026-10-04T14:02 | d-media | Other EASD 2026 data (not in the readout set) | 2026-09-30 | 2026-10-10 | A potential winning approach Results were presented at the European Association for the Study of Diabetes in Milan, Italy. |
| uae-glp1 | [gemini-only]/p0348 | Gemini redirect | google | 2026-10-06T14:04 | d-media | Other EASD 2026 data (not in the readout set) | 2026-10-05 | 2026-10-10 | [quotation withheld: page cited only by Gemini] |
| uae-glp1 | [gemini-only]/p0770 | Gemini redirect | google | 2026-10-06T14:04 | d-media | OCTANE (switch to oral semaglutide, real-world), LBA 59 | 2026-10-05 | 2026-10-10 | [quotation withheld: page cited only by Gemini] |
| uae-glp1 | [gemini-only]/p0917 | Gemini redirect | google | 2026-10-06T14:04 | d-media | OCTANE (switch to oral semaglutide, real-world), LBA 59 | 2026-09-30 | 2026-10-10 | [quotation withheld: page cited only by Gemini] |